Attorneys for Mylan Laboratories Inc. said the generic drug maker will appeal a ruling barring it from marketing a generic version of Pfizer Inc.’s popular high blood pressure medication, Norvasc.

Pfizer sued Mylan in 2002, claiming Mylan infringed on its patent for Norvasc. Mylan acknowledged infringing on the patent, but said it was invalid because it contained the wrong formula.